First Brands Group debt targeted by Apollo Global Management - report
Elevance Health, Inc. (NYSE:ELV) announced on Thursday that its officers expect to reaffirm the company’s full-year 2025 earnings guidance in upcoming meetings with investors. According to a statement released in a U.S. Securities and Exchange Commission filing, Elevance Health continues to project shareholders’ earnings for 2025 to be approximately $24.10 per diluted share, which includes about $5.90 per diluted share of net unfavorable items. Excluding these items, the company maintains its adjusted earnings outlook at roughly $30.00 per diluted share.
The company also stated that it expects to reaffirm its guidance for a full-year 2025 benefit expense ratio of approximately 90.0%.
Elevance Health noted that these expectations reflect management’s current view of market conditions, operational performance, regulatory and policy factors, and key business assumptions such as cost trends and medical claims payable estimates. The company stated that actual results could differ materially if business factors or assumptions change.
This information is based on a press release statement included in Elevance Health’s current report filed with the SEC.
In other recent news, Elevance Health reported its second-quarter 2025 earnings, revealing adjusted earnings per share of $8.84, which aligned with consensus estimates, while revenue reached $49.8 billion, approximately 2.8% above expectations. Despite these figures, the company reduced its earnings per share outlook by $4.50, translating to a $1.3 billion decrease in pre-tax income. Analyst firms have reacted to these results with various adjustments to their price targets. UBS maintained its Buy rating and set a price target of $435, citing Medicaid cost pressures as a factor in its decision. Meanwhile, Bernstein lowered its price target to $445 from $487, maintaining an Outperform rating due to pressures from ACA and Medicaid. TD Cowen also adjusted its price target to $330 from $484, attributing the change to pressures in the Health Insurance Exchange and Medicaid segments. Additionally, UBS revised its price target to $435 from $484, maintaining a Buy rating despite the challenges. In governance news, Elevance Health appointed Steve Collis to its board of directors, effective August 1, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.